By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that its full-year 2009 revenues increased 65 percent as the firm entered into its commercial phase through the launch of colorectal cancer tests.

The German molecular diagnostics firm reported full-year revenues of €4.3 million ($5.8 million), up 65 percent from €2.6 million for FY 2008.

Its loss before interest and tax was €10.2 million versus a loss of €12.8 million for 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.